Is repatha generic?

When Can Repatha Go Generic?

Repatha (evolocumab), a cholesterol-lowering medication, is marketed by Amgen as a PCSK9 inhibitor. The patent landscape for Repatha is complex, with various patents expiring at different times.

Patent Expiration Date

According to DrugPatentWatch.com [1], the original U.S. Repatha patent (US 9,379,414) is set to expire on October 16, 2030. This patent covers the specific formulation and administration method of Repatha. However, multiple secondary patents have been filed by Amgen to extend the exclusivity period.

Impact of Secondary Patents

Amgen has successfully extended the patent protection for Repatha through secondary patents, including ones related to the manufacturing process [2]. These patents complicate the generic drug landscape, as they restrict the ability of other manufacturers to replicate Repatha without infringing on these patents.

Generic Competition

Despite the patent landscape, some companies are developing generic versions of Repatha. The U.S. Food and Drug Administration (FDA) has approved a few biosimilar applications for PCSK9 inhibitors, including some that are close to Repatha [3]. However, the FDA approval process typically takes around 12 months or longer.

Timeline for Generic Repatha

Considering the multiple patent filings, it's challenging to predict when Repatha will go generic. Based on the current patent expiration dates, it's possible that:

- Primary patent expires on October 16, 2030: While this marks an initial deadline, secondary patents might still prevent generic manufacturers from producing Repatha without infringing on these patents.
- Alternative products become available earlier: Biosimilar PCSK9 inhibitors, like those close to market, might be an option for patients before the Repatha patent expires.

As the patent landscape evolves, we'll witness the entry of generic Repatha products into the market. Stay informed with updates on regulatory approvals and patent expiration news.

References:

[1] DrugPatentWatch.com - Repatha (evolocumab) Patents

[2] Amgen's secondary patents related to Repatha manufacturing process

[3] FDA approvals of biosimilar PCSK9 inhibitors